KORU Medical Systems, Inc.’s KRMD share price has surged by 5.80%, which has investors questioning if this is right time to ...

With biosimilars to AstraZeneca’s blockbuster rare blood disease med Soliris recently available in the U.S., nonprofit health ...

Researchers determined patients with paroxysmal hemoglobinuria may benefit from receiving ravulizumab over the long term.

RLYB212 Phase 2 PK Results Did Not Achieve Target Concentrations, Including Minimum Target Concentration Required for Efficacy – ...

Teva and Samsung Bioepis have launched Epysqli, a cost-saving Soliris biosimilar, offering a 30% discount and new hope for ...

Bkemv is being offered at 10% off Soliris, and Epysqli is offered at 30% below Soliris. Both biosimilars treat several of the same rare immune diseases as Soliris.

for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor ...

Rallybio is pushing RLYB116, currently in Phase I trials, for diseases resulting in rare disorders of the complement pathway, including paroxysmal nocturnal hemoglobinuria (PNH), antiphospholipid ...